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General practiceWe read with interest the recent paper by Maurer and colleagues
describing the attitudes toward seasonal and H1N1 vaccination and
vaccination uptake among US adults (Maurer et al., 2010). They found
the 2009 inﬂuenza A(H1N1) vaccine uptake as considerably lower
than seasonal vaccine uptake, which is not consistent with vaccina-
tion rates of patients at-risk we found in the Netherlands.
We studied the effect of pandemic inﬂuenza A(H1N1) on the
relatively high vaccination rate for seasonal inﬂuenza of the Dutch
National Inﬂuenza Prevention Programme (NIPP) (seeBox1) in thepast
years (Kroneman et al., 2003; Blank et al., 2009), and identiﬁed the
relationships between vaccination rates for seasonal and A(H1N1)
inﬂuenza in at-risk groups and staff in general practices. In a
retrospective cohort study of at-risk groups (2009–2010) data were
extracted on age, gender, diagnoses (based on medical history and
medication), and vaccines from electronicmedical records in 72 general
practices (262,958 listed patients). The practices belong to a represen-
tative Dutch network of general practices, LINH, (www.linh.nl, Tacken
et al., 2004). Practice staff was questioned by a written survey aboutBox 1. Seasonal ﬂu vaccination and A(H1N1) pand
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Open access under the Elsevier OA license.their own vaccination; their vaccination rate was calculated separately
for doctors and nurses. By sharing our data, we want to show that it is
possible to reach relatively high uptake rates for pandemic as well as
seasonal vaccinations using a combined strategy.
Having satisﬁed themselves to the vaccines safety and effective-
ness, the Dutch government decided to augment the regular seasonal
2009–2010 NIPP with vaccination for inﬂuenza A(H1N1). Both types
of vaccinations were made available free-of-charge to general
practices for the at-risk groups and for practice staff. Two doses –at
least two weeks apart– were scheduled, with the pandemic A(H1N1)
vaccination started two weeks after the seasonal inﬂuenza vaccine.
(Gezondheidsraad, 2009).
In our study, 83,524 patients were identiﬁed as at-risk of
developing serious complications from inﬂuenza (31.8%). Offering
the separate vaccinations in general practice against seasonal and A
(H1N1) inﬂuenza for groups at-risk resulted in a vaccination rate of
70.4% and 71.9% respectively. We found 63.5% of the groups at-risk
were vaccinated using both vaccines. The vaccination rates for A
(H1N1) and seasonal inﬂuenza were very similar in the different
indication groups.
Information on vaccination status of practice staff was received from
64 practices (88.9%) with 189 general practitioners and 299 practice
nurses. The vaccination rate among general practitioners was 88.9% for
A(H1N1) vaccinations and74.1% for seasonal inﬂuenza, but surprisingly,
among the practice nurses the rates were signiﬁcantly lower (pb .001):
73.6% and 54.2% respectively. The vaccination rate of practice staff as
well as of the patients at-risk was quite high that could explain whywe
did not ﬁnd any signiﬁcant correlation between them.emic vaccination in the Netherlands in 2009.
185Letter to the EditorBecause of the stable results of the seasonal vaccination rate, we
concluded that overall, the A(H1N1) vaccination did not affect the
high vaccination rate for seasonal inﬂuenza. The uptake in the groups
at-risk was comparable for A(H1N1) and seasonal inﬂuenza. The
Dutch combined campaign was successful in terms of achieving high
immunization rates on at-risk patients. Limiting the A(H1N1)
vaccination rate to the at-risk groups probably contributed to higher
Dutch vaccination rates in comparison to other countries.
Adherence to future (pandemic) vaccine recommendations issued in
the vaccine campaigns, will be dependent on the current view of the
inﬂuenza pandemic in the at-risk groups as well as healthcare workers,
in which the probability of the number of people that will die plays a
devastating role (Paget, 2009). A campaign in which an extra
vaccination is introduced in a structural prevention programme seems
to facilitate its implementation and stimulates the vaccination rate.
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